Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Other messenger RNAs with seed-region complementarity refers to the broad set of unintended transcripts targeted by RNA interference (RNAi) therapeutics, such as siRNAs or miRNA mimics (Jackson et al., 2003, Nature Biotechnology). This phenomenon occurs when the 'seed region'—typically nucleotides 2 through 8 of the small RNA guide strand—finds a complementary match in the 3' untranslated region (UTR) of a non-target mRNA (Birmingham et al., 2006, Nature Methods). Because this binding mimics the natural regulatory mechanism of endogenous microRNAs, it can lead to the degradation or translational repression of hundreds of unintended genes (Filipowicz et al., 2008, Nature Reviews Genetics). In drug discovery, these off-target effects are a significant hurdle, as they can cause cellular toxicity or lead to false-positive results in functional screens (Burchard et al., 2009, Nature Biotechnology). Modern therapeutic design employs chemical modifications, such as 2'-O-methyl substitutions on the ribose ring, and advanced bioinformatic filtering to minimize these interactions and improve the safety profile of RNA-based drugs (Janas et al., 2018, Nature Communications). Consequently, this 'target' is actually a primary source of toxicity that must be avoided rather than a therapeutic objective.
Unintended binding of the siRNA or miRNA seed region (nucleotides 2-8) to complementary sequences in the 3' untranslated regions (UTRs) of non-target mRNAs, leading to gene silencing via the RNA-induced silencing complex (RISC).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other messenger RNAs with seed-region complementarity (Off-target mRNAs).